EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18–49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years

Essack Mitha, Murdo Ferguson, Agatha Cathrine Wilhase, Ferdinandus De Looze iD, Marie-Louise Vachon, Helen Stacey, Roy Rasalam, Minoru Nozaki, William B Smith iD, Tino F Schwarz, Hiwot Amare Hailemariam, Quentin Deraedt iD und 8 weitere

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciag058 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Essack Mitha und 19 weiteren Autor:innen. Beteiligte Einrichtung: Newtown Clinical Research Centre, Johannesburg, South Africa. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Viral Fusion Proteins, Respiratory Syncytial Virus, Human. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine (adjuvanted RSVPreF3) is approved for ≥60-year-olds and 50–59-year-olds at increased risk of RSV disease. We evaluated the vaccine's immunogenicity and safety in 18–49-year-olds at increased risk of RSV disease due to certain chronic conditions.

Methods

This open-label, multicountry phase 3b trial included 18–49-year-olds at increased risk (at-risk 18–49 group) and a control group of ≥60-year-olds with or without chronic conditions (≥60 group). Primary objective was to demonstrate immunological noninferiority to adjuvanted RSVPreF3 in the at-risk 18–49 versus ≥60 group, based on group RSV-A/RSV-B geometric mean titer ratios and seroresponse rate differences 1 month postvaccination. Humoral, cell-mediated immunogenicity, and safety were assessed until 6 months postvaccination.

Results

Overall, 1458 adults were vaccinated. Immunological noninferiority was demonstrated in the at-risk 18–49 versus ≥60 group at 1 month postvaccination. Both groups showed increased RSV-A/RSV-B neutralizing titers and RSVPreF3-specific CD4+ T-cell frequencies at 1 month postvaccination that declined but remained above baseline at 6 months. Solicited events were more frequent in the at-risk 18–49 (84.3%) than in the ≥60 group (69.4%); most were mild-to-moderate and transient. Rates and intensity of unsolicited adverse events (AEs) were comparable across groups, with low reporting of serious AEs and AEs of special interest.

Conclusions

Adjuvanted RSVPreF3 was immunologically noninferior in 18–49-year-olds with underlying conditions compared with ≥60-year-olds in whom efficacy was previously demonstrated, supporting efficacy inference in this younger population. Up to 6 months postvaccination, the vaccine elicited robust immune responses, and the safety profile was acceptable. Clinical Trial Registration: NCT06389487

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesViral Fusion ProteinsRespiratory Syncytial Virus, HumanAdjuvants, ImmunologicImmunogenicity, VaccineHumansFemaleAntibodies, ViralMaleMiddle AgedAdultAdolescentYoung AdultAntibodies, NeutralizingAged

Stichwörter der Autor:innen

adjuvanted RSVPreF3noninferior immunogenicityrespiratory syncytial virussafetyyoung adults

Substanzen

Respiratory Syncytial Virus VaccinesAntibodies, ViralViral Fusion ProteinsAdjuvants, ImmunologicF protein, human respiratory syncytial virusAntibodies, Neutralizing

Autor:innen und Institutionen

  • Newtown Clinical Research Centre, Johannesburg, South Africa.
  • Colchester Research Group, Truro, Canada.
  • REIMED Pty., Boksburg, South Africa.
  • Momentum Clinical Research Wellers Hill, Brisbane, Australia.
  • Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, Canada.
  • Diablo Clinical Research, Walnut Creek, California, USA.

ORCID-Profile: Ferdinandus De Looze, William B Smith, Quentin Deraedt

Förderung

  • GSK

Zitieren

APA

Mitha, E., Ferguson, M., Wilhase, A. C., De Looze, F., Vachon, M. L., Stacey, H., Rasalam, R., Nozaki, M., Smith, W. B., Schwarz, T. F., Hailemariam, H. A., Deraedt, Q., Gérard, C., Vanden Abeele, C., Damaso, S., Descamps, D., Hill, J., Dasyam, D., Van Gucht, J., & Hulstrøm, V. (2026). Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18–49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag058

Vancouver

Mitha E, Ferguson M, Wilhase AC, De Looze F, Vachon ML, Stacey H, et al. Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18–49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag058

BibTeX
@article{Mitha2026,
  author = {Mitha, Essack and Ferguson, Murdo and Wilhase, Agatha Cathrine and De Looze, Ferdinandus and Vachon, Marie-Louise and Stacey, Helen and Rasalam, Roy and Nozaki, Minoru and Smith, William B and Schwarz, Tino F and Hailemariam, Hiwot Amare and Deraedt, Quentin and Gérard, Catherine and Vanden Abeele, Carline and Damaso, Silvia and Descamps, Dominique and Hill, Judith and Dasyam, Dileep and Van Gucht, Jonathan and Hulstrøm, Veronica},
  title = {Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18–49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciag058}
}
Kostenlos starten →